Medgenics Inc (NASDAQ:GNMX) was downgraded by research analysts at Jefferies Group LLC to a “hold” rating in a report released on Tuesday. They currently have a $2.50 target price on the stock. Jefferies Group LLC’s target price indicates a potential upside of 13.12% from the company’s current price.
Medgenics (NASDAQ:GNMX) opened at 2.21 on Tuesday. The stock’s market capitalization is $82.01 million. The firm’s 50-day moving average is $5.01 and its 200 day moving average is $5.27. Medgenics has a 1-year low of $2.05 and a 1-year high of $17.75.
Your IP Address:
Several hedge funds and other institutional investors have recently made changes to their positions in GNMX. Broadfin Capital LLC acquired a new position in shares of Medgenics during the fourth quarter valued at $17,458,000. Opaleye Management Inc. acquired a new position in shares of Medgenics during the fourth quarter valued at $7,770,000. State Street Corp increased its position in shares of Medgenics by 15.4% in the fourth quarter. State Street Corp now owns 345,698 shares of the company’s stock valued at $1,789,000 after buying an additional 46,149 shares during the last quarter. Birchview Capital LP acquired a new position in shares of Medgenics during the fourth quarter valued at $249,000. Finally, Oxford Asset Management acquired a new position in shares of Medgenics during the fourth quarter valued at $249,000. 44.69% of the stock is owned by institutional investors and hedge funds.
Receive News & Ratings for Medgenics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medgenics Inc and related companies with MarketBeat.com's FREE daily email newsletter.